Welcome to our dedicated page for Zentalis Pharmaceuticals SEC filings (Ticker: ZNTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zentalis Pharmaceuticals, Inc. SEC filings document clinical oncology disclosures, financial results, governance matters and capital actions for the ZNTL public company. Recent Form 8-K filings cover azenosertib program updates, Regulation FD corporate presentations, clinical-trial and scientific-presentation exhibits, and results of operations furnished with business updates.
The company’s proxy materials describe board composition, executive compensation, equity awards and shareholder voting matters. Other event filings also record corporate governance changes and completed common stock repurchase activity, alongside cautionary risk language related to clinical development, regulatory pathways and forward-looking statements.
Campbell Shannon reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director Shannon Campbell received an equity grant in the form of restricted stock units. The award covers 114,200 shares of common stock at no purchase price, granted under the company’s Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, contingent on continued board service, resulting in 114,200 shares reported as directly owned after this grant.
Zentalis Pharmaceuticals, Inc. director Campbell Shannon filed an initial Form 3 insider ownership report. The excerpt shows no reported transactions, no derivative positions, and no holding entries, indicating that this filing is purely administrative disclosure of insider status without visible trading activity.
Zentalis Pharmaceuticals expanded its Board of Directors from six to seven members and appointed Shannon Campbell as a Class I director. Her term runs until the 2027 annual stockholder meeting, and she will also serve on the Board’s Compensation Committee.
Campbell will be paid under the company’s standard non-employee director program, including a $45,000 annual cash retainer for Board service and an additional $7,500 annual retainer for Compensation Committee membership. As a new director, she received 114,200 restricted stock units, calculated as 0.16% of the common shares outstanding before grant, vesting in equal installments over three years.
After six months of service, she will become eligible for an annual equity award equal to 0.08% of shares outstanding before each grant, which generally vests in full by the next annual meeting or the first anniversary of grant. All of Campbell’s director equity awards vest in full upon a change in control, subject to her continued service, and she has entered into the company’s standard indemnification agreement for directors and officers.
Zentalis Pharmaceuticals reported updated Phase 1b MUIR trial results for its investigational WEE1 inhibitor azenosertib combined with paclitaxel in platinum-resistant ovarian cancer (PROC). In 46 all-comer PROC patients across four dose cohorts, the regimen achieved a 39.1% overall response rate and 58.7% clinical benefit rate, with median duration of response of 5.6 months and median progression-free survival of 7.3 months as of the December 1, 2025 cutoff. These outcomes are described as encouraging versus historical paclitaxel monotherapy data of roughly 30% response and 4-month median progression-free survival.
At the 250 mg intermittent 5:2 azenosertib dose (12 patients), overall response rate was 50.0%, clinical benefit rate 66.7%, and median duration of response 9.2 months, supporting this as a potential optimal combination dose. Activity appeared similar in Cyclin E1‑positive and Cyclin E1‑negative tumors. The safety profile was characterized as manageable: common treatment-related adverse events included fatigue, anemia, nausea, and neutropenia, with Grade ≥3 neutropenia in 30.4% and anemia in 19.6% of patients, and one Grade 5 sepsis event considered related to azenosertib.
Zentalis Pharmaceuticals reported a narrower quarterly loss while advancing its lead cancer drug azenosertib. For the three months ended March 31, 2026, net loss was $35.4 million (or $0.50 per share), compared with $48.3 million (or $0.67 per share) a year earlier, helped by lower restructuring and stock-based compensation expenses.
Research and development spending was $28.7 million, reflecting higher clinical and manufacturing costs as the DENALI and ASPENOVA trials progress, while general and administrative expenses declined to $9.1 million. Operating cash use was $33.0 million in the quarter.
Cash, cash equivalents and marketable debt securities totaled $211.8 million as of March 31, 2026, and management believes this will fund operations into late 2027. The company began Phase 3 ASPENOVA in Cyclin E1-positive platinum-resistant ovarian cancer, triggering a subsequent $7.0 million milestone payment under its Recurium license, and expects topline DENALI Part 2 data by year-end 2026.
Zentalis Pharmaceuticals reported a first-quarter 2026 net loss of $35.4 million, improving from $48.3 million a year earlier, with net loss per share narrowing to $0.50 from $0.67. Total operating expenses fell to $37.9 million from $45.6 million, reflecting the absence of a prior-year restructuring charge and lower general and administrative costs, partly offset by higher clinical spending.
The company ended March 31, 2026 with $211.8 million in cash, cash equivalents and marketable securities, which it believes will fund operations into late 2027. Zentalis advanced its lead WEE1 inhibitor azenosertib, selecting a 400mg once-daily 5:2 dosing schedule as the pivotal monotherapy dose in platinum-resistant ovarian cancer and expanding the Phase 2 DENALI trial, with topline data expected by year-end 2026. The Phase 3 ASPENOVA confirmatory trial has dosed its first patient, aiming to support full approval and ex-US registrations in Cyclin E1-positive platinum-resistant ovarian cancer.
Zentalis Pharmaceuticals has dosed the first patient in ASPENOVA, its global Phase 3 trial of investigational WEE1 inhibitor azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. The randomized study plans to enroll about 420 patients, comparing oral azenosertib 400mg once daily on a 5-days-on, 2-days-off schedule to standard single-agent chemotherapy.
ASPENOVA is designed as a confirmatory trial to support potential full approval, alongside the Phase 2 DENALI study, which is intended to underpin an accelerated approval application with a topline readout targeted by year-end 2026. Azenosertib, which has U.S. FDA Fast Track Designation for this setting, is being developed with a biomarker-driven strategy in collaboration with major gynecologic oncology trial groups.
Zentalis Pharmaceuticals, Inc. is asking stockholders to vote at its fully virtual 2026 Annual Meeting on June 16, 2026 at 10:00 a.m. ET. Holders of 71,186,348 shares of common stock as of April 20, 2026 may vote online, by phone, mail or during the webcast.
Stockholders will elect two Class III directors (David Johnson and Jan Skvarka) to terms ending in 2029, ratify Ernst & Young LLP as auditor for 2026, and cast an advisory say‑on‑pay vote on named executive officer compensation. In 2025, the board determined corporate goals were achieved at 105%, and annual bonuses for eligible executives were paid at 105% of target.
Zentalis Pharmaceuticals furnished an update on its WEE1 inhibitor azenosertib, highlighting new preclinical and real‑world data presented at the AACR 2026 meeting in San Diego. In triple‑negative breast cancer models, azenosertib showed 42–99% tumor growth inhibition as monotherapy and drove stronger responses when combined with antibody‑drug conjugates or paclitaxel, including complete responses in 7 of 8 mice in an ADC‑resistant model.
Real‑world analyses in high‑grade serous ovarian cancer showed Cyclin E1‑positive patients had shorter time to next treatment after first‑line therapy, at 13.2 and 14.9 months in two groups versus 19.5 months for Cyclin E1‑negative patients, underscoring a poor‑prognosis population Zentalis is targeting with late‑stage azenosertib studies.